Home
Resources
Publications
A Retrogen Plasmid-Based Vaccine Generates High Titer Antibody Responses Against the Autologous Cancer Antigen Survivin and Demonstrates Anti-Tumor Efficacy

A Retrogen Plasmid-Based Vaccine Generates High Titer Antibody Responses Against the Autologous Cancer Antigen Survivin and Demonstrates Anti-Tumor Efficacy

William K Decker, Jianxia Qiu, Farhang Farhangfar, Jenny H Hester, Dario C Altieri, Augustine Y Lin

Cancer Lett. 2006 Jun 8;237(1):45-55.

PMID: 16019131

Abstract:

We describe the use of retrogen plasmid-based vaccine technology to break tolerance and to generate a robust, dose-dependent antibody response against the self cancer antigen, survivin. We further demonstrate that this phenomenon is due to the incorporation of the survivin antigen into the retrogen system rather than to some peculiarity unique to survivin. In contrast to other genetic immunization methods designed to produce antibody responses, the retrogen system results in a broad range of antibody isotypes, indicative of both a Th-1 and a Th-2 CD4+ response. Additional evidence of a Th-1 response is demonstrated by tumor growth inhibition in a mouse model of colon cancer metastasis. We speculate that this cost-effective technology could one day bolster or even supplant the use of monoclonal antibodies in the targeting of cell surface cancer antigens.

Chemicals Related in the Paper:

Catalog Number	Product Name	Structure	CAS Number	Price
IAR4248964	Monoclonal Anti-DNA Ligase I antibody produced in mouse			Price

As a specialist in analytical chemical Products, Alfa Chemistry offers consumers a wealth of raw materials and a full range of technologies and services.

QUICK LINKS

HEADQUARTERS

Tel:

Fax:

Email: